The Current Role of Bevacizumab in the Treatment of Hereditary Hemorrhagic Telangiectasia–Related Bleeding

Research output: Contribution to journalEditorial

Original languageEnglish (US)
Pages (from-to)130-132
Number of pages3
JournalMayo Clinic Proceedings
Volume93
Issue number2
DOIs
StatePublished - Feb 2018

Fingerprint

Hereditary Hemorrhagic Telangiectasia
Hemorrhage
Bevacizumab

ASJC Scopus subject areas

  • Medicine(all)

Cite this

The Current Role of Bevacizumab in the Treatment of Hereditary Hemorrhagic Telangiectasia–Related Bleeding. / Gossage, James R.

In: Mayo Clinic Proceedings, Vol. 93, No. 2, 02.2018, p. 130-132.

Research output: Contribution to journalEditorial

@article{715891bad8564ca88b20d3e16916089e,
title = "The Current Role of Bevacizumab in the Treatment of Hereditary Hemorrhagic Telangiectasia–Related Bleeding",
author = "Gossage, {James R.}",
year = "2018",
month = "2",
doi = "10.1016/j.mayocp.2017.12.019",
language = "English (US)",
volume = "93",
pages = "130--132",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "2",

}

TY - JOUR

T1 - The Current Role of Bevacizumab in the Treatment of Hereditary Hemorrhagic Telangiectasia–Related Bleeding

AU - Gossage, James R.

PY - 2018/2

Y1 - 2018/2

UR - http://www.scopus.com/inward/record.url?scp=85041105285&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041105285&partnerID=8YFLogxK

U2 - 10.1016/j.mayocp.2017.12.019

DO - 10.1016/j.mayocp.2017.12.019

M3 - Editorial

C2 - 29395348

AN - SCOPUS:85041105285

VL - 93

SP - 130

EP - 132

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 2

ER -